TickerHumNYSE · Healthcare · Medical Devices
Stryker Corporation (SYK)
As of Nov 11, 4:00 PM ET, Stryker (SYK) last traded at $318.83, down 1.68% on the day. Its TickerHum research score is 59/100 (average). It reported revenue of $26.3B for the twelve months ending 2026-09-30, up 7.9% year over year, with a 20.7% operating margin.
Ratings
- Valuation: 64/100 — Strongest input: price / sales (ttm) 4.6x. Weakest: price / earnings (ttm) 34.0x.
- Growth: 59/100 — Strongest input: diluted eps growth (ttm, yoy) +23.4 %. Weakest: revenue growth (ttm, yoy) +7.9 %.
- Profitability: 69/100 — Strongest input: gross margin 65.3 %. Weakest: return on equity 15.4 %.
- Financial health: 57/100 — Strongest input: current ratio 2.18. Weakest: cash / long-term debt 0.23.
- Momentum: 39/100 — Strongest input: 6-month return +5.5 %. Weakest: 1-year return -13.2 %.
- Attention: 59/100 — Strongest input: headlines in the last 7 days 57. Weakest: volume vs 3-month average 1.0x.
- Risk resilience: 64/100 — Strongest input: annualised volatility (1y) 32.8 %. Weakest: max drawdown (1y) -30.4 %.
- Data confidence: 100/100 — Based on inputs available 100 %, quote age (hours) 0 h, latest financial period age (days) 43 d.
Reported fundamentals
| Metric | Value | Period |
|---|---|---|
| Revenue | $26.3B | TTM ending 2026-09-30 · 10-Q |
| Revenue growth | 7.9% | TTM ending 2026-09-30 · 10-Q |
| Net income | $3.62B | TTM ending 2026-09-30 · 10-Q |
| Diluted EPS | $9.39 | TTM ending 2026-09-30 · 10-Q |
| Gross margin | 65.3% | TTM ending 2026-09-30 · 10-Q |
| Operating margin | 20.7% | TTM ending 2026-09-30 · 10-Q |
| Net margin | 13.8% | TTM ending 2026-09-30 · 10-Q |
| Free cash flow | $4.57B | TTM ending 2026-09-30 · 10-Q |
| Cash | $3.27B | as of 2026-09-30 · 10-Q |
| Long-term debt | $14.18B | as of 2026-09-30 · 10-Q |
| Debt / equity | 0.60 | as of 2026-09-30 · 10-Q |
Source: SEC EDGAR XBRL company facts (CIK 0000310764).
Prices: Yahoo Finance (public) — Free public Yahoo Finance data. Prices may be delayed and are for information only.